Immune Checkpoint Inhibitors for Non–Small Cell Lung Cancer With Genomic Aberrations

Details

Files
Project Status:
Open for Stakeholder Feedback
Project Line:
Health Technology Review
Project Sub Line:
Systematic Review
Project Number:
RE0050-000

Immune checkpoint inhibitors (ICIs) are approved as monotherapy for non–small cell lung cancer (NSCLC). Metastatic NSCLC with mutations or rearrangements (ALK, EGFR, ROS-1, BRAF, MET, RET) are known to respond poorly to ICIs and should be first treated with targeted drugs and chemotherapy. This systematic review will synthesize the evidence on the benefits of ICIs when used as third-line therapy or beyond for mutated NSCLC.


Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.